Optimal performance and reliability. Qualified and deployed in many harsh environments.Find out more
G&H announces that the EU GALAHAD project has now been completed. GALAHAD (Glaucoma – Advanced, LAbel-free High resolution Automated OCT Diagnostics; was funded by the European Union through its Horizon 2020 programme.
Co-ordinated by G&H Torquay, the project brought together ten partners from across Europe with the common objective of developing hardware, software and know-how to improve the early screening of glaucoma.
GALAHAD finished on schedule at the end of November 2019. Over the last 36 months the project has had a major impact on the development of ultra-high resolution polarisation sensitive optical coherence tomography (UHR-PS-OCT), from advances in components to automated algorithms to process the results. GALAHAD has been very successful in developing components, sub-systems, operational systems (1 µm axial resolution), processes and software related to OCT and has achieved some important results in applying them to glaucoma screening.
The key advances include:
Components (already available as products from G&H)
Sources (products planned to be released in 2020 by NKT)
Spectrometers (customized products available from Ibsen Photonics)
DTU developed numerical all-depth OCT dispersion compensation software
Universitat Politècnica de València (UPV) developed algorithms which set the new state-of-the-art in several areas:
University of Münster (WWU) delivered permanent tissue-like test standards for UHR-PS-OCT testing
WWU reported the first measurement of retinal refractive index as a function of wavelength
Optos assembled two final systems which were characterised with axial resolutions of 1.25 µm (GALAHAD-1) and 1.39 µm (GALAHAD-2)
>150 OCT measurements from various glaucoma models were performed
This work has already contributed to analytical procedures for the refined analysis prediction of visual field characteristics by Rigshospitalet
This live demonstration, on a human volunteer, formed part of the workshop on 8 January 2020 to an audience of researchers and clinicians
This went significantly beyond the planned project scope and was a highly satisfactory conclusion to the project.
This project has received funding from Horizon 2020, the European Union’s Framework Programme for Research and Innovation, under grant agreement No. 732613.